Weekly Recap | Revolution Medicines +0.81%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 07:37 AMRVMD+0.50%
Weekly Recap | Roche -4.04%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 07:34 AMRHHBY+0.50%
Weekly Recap | Lexicon Pharma +1.39%, consensus target above spotWeekly Review·Oct 3, 2026 at 07:11 AMLXRX-4.40%
Weekly Recap | Eli Lilly -3.43%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 07:08 AMLLY+0.02%LLYX-0.15%
Weekly Recap | Corcept Therap +0.11%, a choppy week ends higherWeekly Review·Oct 3, 2026 at 06:34 AMCORT+4.99%
Weekly Recap | Bristol Myers Squibb this week, a quiet, range-bound stretchWeekly Review·Oct 3, 2026 at 06:25 AMBMY-3.83%
Weekly Recap | XLV.US -2.65%, heavy pharma data but sector lagsWeekly Review·Oct 3, 2026 at 05:05 AMXLV+0.72%
Weekly Recap | VG Value -1.62%, trailing the S&P 500 by over a pointWeekly Review·Oct 3, 2026 at 05:03 AMVTV+0.32%
Weekly Recap | VG Health -2.41%, sector news heavy but price softWeekly Review·Oct 3, 2026 at 05:02 AMVHT+0.84%
Weekly Recap | DGRO.US -1.04%, defensive tilt lags the tapeWeekly Review·Oct 3, 2026 at 04:20 AMDGRO+0.38%
Weekly Recap | Vistagen Therap +13.75%, spike and fade after Phase 3 dataWeekly Review·Sep 26, 2026 at 07:18 AMVTGN-6.33%
